Psilocybin may be effective for treatment-resistant depression
Pharmaceutical journal/The pharmaceutical journal – January 01, 2022
Source: OpenAlex
Summary
A single 25mg dose of psilocybin, combined with psychological support, offers significant hope for treatment-resistant depression. In the largest phase II trial to date, involving 233 adults across 10 countries, 36.7% experienced a 50% reduction in depressive symptoms, and 20.3% achieved remission. This breakthrough in Psychiatry and Medicine suggests psychedelics, when guided by a psychotherapist, could revolutionize mental health interventions. Such findings from Psychedelics and Drug Studies highlight psilocybin's potential to alleviate the human and economic burden of severe depression, impacting Psychology and future Digital Mental Health strategies.
Abstract
The largest trial to date of the psychedelic drug psilocybin has shown that, alongside psychological support, a single 25mg dose may improve the symptoms of treatment-resistant depression. The phase II study, published in the New England Journal of Medicine on 3 November 2022, was conducted across 22 sites in 10 countries, including the UK, between […]